I-Mab

I-Mab Announces Portfolio Prioritization of Givastomig as Lead Clinical Program

January 06, 2025 | 19:00

I-Mab, a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer.

I-Mab to Participate at the Piper Sandler Healthcare Conference

November 21, 2024 | 19:00

The 36th Annual Healthcare Conference will be held in New York , December 3-5, 2024

I-Mab Reports Third Quarter 2024 Results

November 14, 2024 | 19:00

I-Mab, a U.S.-based, global biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced financial results for the three and nine months ended September 30, 2024.

I-Mab to Participate at the Truist Securities BioPharma Symposium

October 28, 2024 | 18:00

I-Mab, a US-based, global, biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that management will participate in one-on-one and small group meetings with investors at the Truist Securities BioPharma Symposium on November 7, 2024 .